StockData
Unicycive Therapeutics, Inc. logo

Unicycive Therapeutics, Inc. (UNCY) stock

UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$3.53−0.04 (-1.12%)

Close on Nov 19, 2026Market cap $98.33MP/E –Yield –

Unicycive Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Unicycive Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$33.14M. For fiscal 2025 it was -$29.52M. The highest annual figure on record is -$2.02M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$29.52M–
FY2024Dec 31, 2024-$32.12M–
FY2023Dec 31, 2023-$20.77M–
FY2022Dec 31, 2022-$18.05M–
FY2021Dec 31, 2021-$8.98M–
FY2020Dec 31, 2020-$2.02M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.14M–
Q1 FY2026Mar 31, 2026-$8.44M–
Q4 FY2025Dec 31, 2025-$7.22M–
Q3 FY2025Sep 30, 2025-$7.34M–
Q2 FY2025Jun 30, 2025-$6.96M–
Q1 FY2025Mar 31, 2025-$7.99M–
Q4 FY2024Dec 31, 2024-$9.26M–
Q3 FY2024Sep 30, 2024-$6.25M–
Q2 FY2024Jun 30, 2024-$7.40M–
Q1 FY2024Mar 31, 2024-$9.20M–
Q4 FY2023Dec 31, 2023-$6.31M–
Q3 FY2023Sep 30, 2023-$5.94M–
Q2 FY2023Jun 30, 2023-$4.32M–
Q1 FY2023Mar 31, 2023-$4.20M–
Q4 FY2022Dec 31, 2022-$5.33M–
Q3 FY2022Sep 30, 2022-$5.55M–
Q2 FY2022Jun 30, 2022-$3.64M–
Q1 FY2022Mar 31, 2022-$3.54M–
Q4 FY2021Dec 31, 2021-$2.75M–
Q3 FY2021Sep 30, 2021-$4.72M–
Q2 FY2021Jun 30, 2021-$779.00K–
Q1 FY2021Mar 31, 2021-$731.00K–
Q4 FY2020Dec 31, 2020-$717.00K–
Q3 FY2020Sep 30, 2020-$626.00K–
Q2 FY2020Jun 30, 2020-$336.00K–

More Unicycive Therapeutics figures

See a number that looks wrong?